 | Up a level |
Journal Article
Ansmann, L., Ernstmann, N., Kowalski, C., Wuerstlein, R., Wirtz, M. and Pfaff, H. (2014). Patient participation in multidisciplinary tumor conferences in breast cancer care. Oncol. Res. Treat., 37. S. 82 - 83. BASEL: KARGER. ISSN 2296-5262
Braun, M., Gluz, O., Nitz, U., Christgen, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., Kreipe, H. -H. and Harbecks, N. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer. Oncol. Res. Treat., 39. S. 2 - 3. BASEL: KARGER. ISSN 2296-5262
Christgen, M., Harbeck, N., Gluz, O., Raap, M., Christgen, H., Clemens, M., Malter, W., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Stefek, A., Krabisch, P., Just, M., Graeser, M., Baehner, R., Wuerstlein, R., Nitz, U., Kates, R. and Kreipe, H. (2020). High likelihood of actionable pDifferential impact of prognostic parameters in hormone receptor-positive lobular early breast cancer in the WSG PlanB trialathogenic variant detection in breast cancer genes in women with very early onset breast cancer, but low rate of additional panel genes. Eur. J. Cancer, 138. S. S1 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Fasching, P. A., Fehm, T., Kellner, S., de Waal, J., Rezal, M., Baler, B., Baake, G., Kolberg, H. -C, Guggenberger, M., Warm, N., Harbeck, N., Wuerstlein, R., Deuker, J. -U, Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. -W, Breitbach, G. -P, Janni, W., Landthaler, R., Kohls, A., Rezek, D., Nosslet, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Kuemmel, S., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Hadji, P., Wallwiener, D., Grischice, E. -M, Beckmann, M. W. and Brucker, S. Y. (2014). Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd., 74 (12). S. 1137 - 1144. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Gluz, O., Nitz, U., Christgen, M., Kates, R., Clemens, M., Kraemer, S., Nuding, B., Aktas, B., Kuemmel, S., Reimer, T., Lorenz-Salehi, F., Krabisch, P., Just, M., Augustin, D., Liedtke, C., Svedman, C., Shak, S., Wuerstlein, R., Kreipe, H. and Harbeck, N. (2016). Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer. Eur. J. Cancer, 57. S. S6 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Gluz, O., Nitz, U., Kreipe, H. H., Christgen, M., Kates, R. E., Hofmann, D., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., Kusche, M., Heyl, V., Lorenz-Salehi, F., Just, M., Liedtke, C., Wuerstlein, R. and Harbeck, N. (2015). Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX (R): First prospective survival results from the WSG phase III planB trial. Eur. J. Cancer, 51. S. S311 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Hack, C. C., Haeberle, L., Brucker, S. Y., Janni, W., Volz, B., Loehberg, C. R., Hartkopf, A. D., Walter, C-B, Baake, G., Fridman, A., Malter, W., Wuerstlein, R., Harbeck, N., Hoffmann, O., Kuemmel, S., Martin, B., Thomssen, C., Graf, H., Wolf, C., Lux, M. P., Bayer, C. M., Rauh, C., Almstedt, K., Gass, P., Heindl, F., Brodkorb, T., Willer, L., Lindner, C., Kolberg, H-C, Krabisch, P., Weigel, M., Steinfeld-Birg, D., Kohls, A., Brucker, C., Schulz, V, Fischer, G., Pelzer, V, Rack, B., Beckmann, M. W., Fehm, T., Rody, A., Maass, N., Hein, A., Fasching, P. A. and Nabieva, N. (2020). Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. Breast, 50. S. 11 - 19. EDINBURGH: CHURCHILL LIVINGSTONE. ISSN 1532-3080
Harbeck, N., Gluz, O., Christgen, M., Braun, M., Kuemmel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Kates, R. E., Wuerstlein, R., de Haas, S. L., Kiermaier, A., Kreipe, H. H. and Nitz, U. (2016). Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer. Cancer Res., 76. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Harbeck, N., Gluz, O., Kreipe, H. H., Christgen, M., Svedman, C., Shak, S., Hofmann, D., Kuemmel, S., Nuding, B., Rezai, M., Schumacher, C., Kusche, M., Forstbauer, H., Maass, N., Kraemer, S., Aktas, B., Mohrmann, S., Wuerstlein, R., Kates, R. E. and Nitz, U. (2013). Run-in phase of prospective WSG-ADAPT HR+/ HER2-trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine. Cancer Res., 73. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Biehl, C. M., Schumacher, C., Malter, W., Aktas, B., Forstbauer, H., Tio, J., Grischke, E-M., Kolberg-Liedtke, C., de Haas, S., Deurloo, R. J., Kates, R. E., Zu, C. Eulenburg, Wuerstlein, R., Kreipe, H. and Gluz, O. (2021). Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial. Ann. Oncol., 32. S. S1285 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Harbeck, N., Nitz, U., Christgen, M., Kuemmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., Aktas, B., Malter, W., Forstbauer, H., von Schumann, R., Just, M., Jozwiak, K., Hauptmann, M., Kates, R., Graeser, M., Wuerstlein, R. and Kreipe, H. (2020). De-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs trastuzumab plus ET in early HR+/HER2+breast cancer (BC): ADAPT-TP survival results. Ann. Oncol., 31. S. S1146 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Harbeck, N., Nitz, U. A., Matthias, C., Kates, R., Braun, M., Kummel, S., Schumacher, C., Potenberg, J., Kraemer, S., Kleine-Tebbe, A., Augustin, D., Aktas, B., Forstbauer, H., Tio, J., Liedtke, C., Grischke, E-M, de Haas, S. L., Deurloo, R., Schumacher, J., Wuerstlein, R., Kreipe, H. H. and Gluz, O. (2017). The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC). Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Nabieva, N., Fehm, T., Haeberle, L., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. -C., Guggenberger, M., Warm, M., Harbeck, N., Wuerstlein, R., Deuker, J. -U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Popovic, M., Kuhn, T., Wolf, C., Vollert, H. -W., Breitbach, G. -P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesselt, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Hack, C. C., Schmidt, K., Belleville, E., Brucker, S. Y., Kuemmel, S., Beckmann, M. W., Wallwiener, D., Hadji, P. and Fasching, P. A. (2018). Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. Eur. J. Cancer, 96. S. 82 - 91. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Nabieva, N., Kellner, S., Fehm, T., Haebrle, L., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. -C., Guggenberger, M., Warm, M., Harbeck, N., Wuerstlein, R., Deuker, J. -U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. -W., Breitbach, G. -P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesselt, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kuehn, T., Krauss, T., Thomssen, C., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Brucker, S. Y., Kuemmel, S., Beckmann, M. W., Wallwiener, D., Hadji, P. and Fasching, P. A. (2018). Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. Ann. Oncol., 29 (1). S. 186 - 193. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nitz, U. A., Gluz, O., Christgen, M., Grischke, E. -M, Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2017). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel. Ann. Oncol., 28 (11). S. 2768 - 2773. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Nitz, U. A. D., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H. and Harbeck, N. (2022). De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel (vol 28, pg 2768, 2017). Ann. Oncol., 33 (3). S. 355 - 356. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wuerstlein, R., Gluz, O., Kreipe, H., Kates, R., Degenhardt, T., Liedtke, C., Shak, S., Nitz, U. and Harbeck, N. (2011). Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis). Eur. J. Cancer, 47. S. S33 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 0959-8049
Wuerstlein, R., Kates, R., Gluz, O., Grischke, E. M., Schem, C., Thill, M., Hasmueller, S., Koehler, A., Otremba, B., Griesinger, F., Schindlbeck, C., Trojan, A., Otto, F., Knauer, M., Pusch, R. and Harbeck, N. (2019). Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study. Breast Cancer Res. Treat., 175 (2). S. 389 - 400. NEW YORK: SPRINGER. ISSN 1573-7217
Wuerstlein, R., Kowalski, C., Diener, S., Krebs, S., Pfaff, H. and Harbeck, N. (2011). Associations between Breast Cancer Patients' Satisfaction with Nursing Staff and Hospital Characteristics, Results of a German Multicenter Study. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445